Skip to content
Home/Companies/Healthcare/Avalyn Pharma
Avalyn Pharma

Avalyn Pharma

Healthcare·France·Exited 2026·Held 9yr
Entry
2017
Hold
9yr
Exit
2026

Who owns Avalyn Pharma?

Avalyn Pharma was owned by Andera Partners through BioDiscovery 5 (2017 vintage) from 2017 to 2026, exited via IPO.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQFrance
SectorHealthcare
Websitewww.avalynpharma.com
Exit Type
IPO
Buyer
MOIC
–
Exit Year
2026

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Amolyt Pharma
Exited 2024
HealthcareFrance· 2021
to
Evommune
Evommune
Exited 2025
HealthcareFrance· 2021
to
Nyxoah
Nyxoah
Active
HealthcareBelgium· 2020
AgoMab
AgoMab
Exited 2026
HealthcareFrance· 2019
to
AM Pharma
AM Pharma
Active
HealthcareNetherlands· 2019
Arvelle
Exited 2021
HealthcareSwitzerland· 2019
to

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
A Place for Mom
A Place for Mom
Active
Silver LakeUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abbisko Healthcare
Active
The Carlyle GroupChina
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Track Avalyn Pharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Avalyn Pharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue